PALO ALTO, Calif., August 12, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic (CDx) to select patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations for treatment with ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody dr
PALO ALTO, Calif., August 08, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA.
PALO ALTO, Calif., & CAMBRIDGE, Mass., August 08, 2022--Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results are being reported today at the International Association for the Study of Lung Cancer (IASLC)